| Hazard Information | Back Directory | [Description]
GSK2793660 is a irreversible covalent α,β-unsaturated amide based DPP1 inhibitor currently in clinical trials for the treatment of cystic fibrosis, noncystic fibrosis bronchiectasis, ANCA-associated vasculitis and bronchiectasis. | [Uses]
GSK2793660 hydrochloride is an orally active, irreversible cathepsin C (CTSC) inhibitor for bronchodilation studies[1]. | [References]
[1] Bruce E Miller, et al. Epithelial desquamation observed in a phase I study of an oral cathepsin C inhibitor (GSK2793660). Br J Clin Pharmacol. 2017 Dec;83(12):2813-2820. DOI:10.1111/bcp.13398 |
|
|